Drugs in R&D · 2004 · Review · PMID 15230633
Explore the library
Limited human evidenceSynthetic growth-hormone-releasing peptide (pralmorelin)
GHRP-2
GHRP-2, also known as pralmorelin, is a synthetic growth hormone secretagogue. Human physiology and diagnostic research do not make it an FDA-approved performance treatment.
Also indexed as: Pralmorelin
A clear starting point
GHRP-2, also known as pralmorelin, is a synthetic growth hormone secretagogue. Human physiology and diagnostic research do not make it an FDA-approved performance treatment.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
Ghrelin / GH–IGF-1
GHRP-2, also known as pralmorelin, is a synthetic growth hormone secretagogue. Human physiology and diagnostic research do not make it an FDA-approved performance treatment.
- Targets & processes
- Ghrelin / GH–IGF-1
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
Human endocrine responses and GH-stimulation testing.
What this does not establish
Diagnostic or hormone-response research does not establish performance benefits. Non-US diagnostic use is not US FDA approval.
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
Endocrine and glucose effects are concerns. FDA describes serious adverse-event reports including infection and pancreatitis; causality was not established.
Contraindications & cautions
Not an exhaustive contraindication review. Endocrine and glucose effects are concerns. FDA describes serious adverse-event reports including infection and pancreatitis; causality was not established.
Medication & supplement interactions
Interaction information is incomplete. Endocrine and glucose effects are concerns. FDA describes serious adverse-event reports including infection and pancreatitis; causality was not established.
Regulatory status · United States
Not FDA-approved. No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Read the official sourceThis is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.